期刊文献+

丙型肝炎患者自身抗体检测的临床意义 被引量:1

暂未订购
导出
摘要 目的探讨丙型肝炎患者血清中自身免疫性抗体的检出率与疾病的相关机理。方法对89例丙型肝炎患者血清和20例体检健康者血清进行抗核抗体(ANA)、ENA抗体、抗线粒体抗体(AMA)、抗平滑肌抗体(SMA)、抗肝膜抗体(LMA)、类风湿因子(RF)等自身抗体检测。结果①丙型肝炎伴ANA、ENA抗体等6种自身抗体阳性率高于正常对照组(P<0.05),其中RF的阳性检出率最高(30.34%)。②急性丙肝组患者阳性检出率为43.75%;慢性丙肝组阳性检出率36.99%,两组比较差异无显著性(χ2=0.25,P>0.05)。③单纯抗-HCV阳性的58例中自身抗体阳性者25例,检出率43.10%;HCV RNA阳性的31例中9例抗体阳性,检出率29.03%。结论HCV感染过程中机体普遍存在自身免疫现象,应引起重视。
作者 梁仲城
出处 《右江民族医学院学报》 2005年第5期647-649,共3页 Journal of Youjiang Medical University for Nationalities
  • 相关文献

参考文献6

  • 1Mshior S, Hoshi Y, Takeda K, et al. Non2A , non2B hepatitis specificautibodies at host derived epitope : implication for an autoimmune process [J]. Lancet,1990,336(12):1400-1403.
  • 2刘文恩,谭德明,张铮,范学工,欧阳颗.慢性丙型肝炎自身免疫发病机制的研究[J].湖南医科大学学报,2000,5(4):367-370. 被引量:8
  • 3PawIotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis : a prospective case control study [J]. Hepatology,1994,19(4):841-848.
  • 4Buskila D, Shnaider A, Neumann L, et al. To test autoimmunation anties in the chronic HCV patients [J]. Semin Arthritis Rheum,1998,28(2):107-113.
  • 5Kammer AR, Van der Burg SH, Grabsoheid B, et al. HCV and autoimmune [J]. J Exp Med,1999,190(2):169-176.
  • 6Lenzi M, Ballardini G, Pusconl M, et al. To test anti2HCV in autoimmune hepatitis patients [J]. Lancet,1990,35(4):258-259.

二级参考文献10

  • 1[1] Bettinardi A, Brugnoni D, Quros-Roldan E, et al. Mi ssense mutations in the Fas gene resulting in autoimmune lymphoproliferative syn drome: A molecular and immunological analysis[J]. Blood, 1997,89:902-909.
  • 2[2] Dianzani U, Bragardo M, DiFranco D, et al. Deficiency of the Fas apop tosis pathway without Fas gene mutation in pediatric patients with autoimmunity lympho proliferation[J]. Blood, 1997,89:2871-2879.
  • 3[3] Yufu Y, Choi I, Hirase N, et al. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma: higher concentrations in angioimmunoblastic T-ce ll lymphoma[J]. Am J Hematol, 1998,58(4):334-336.
  • 4[4] Shimaoka Y, Hidaka Y, Okumura M, et al. Serum concentration of solu ble Fas in patients with autoimmune thyroid diseases[J]. Thyroid, 1998,8(1):43 -47.
  • 5[5] Jodo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/A po-1(CD95) and is molecular structure in patients with systemic lupus erythemat osus(SLE) and other autoimmune diseases[J]. Clin Exp Immunol, 1997,107(1):89-9 5.
  • 6[6] Stehman-Breen C, Alpers SCE, Couser WG, et al. Hepatitis C virus ass ociated membranous glomerulonephritis[J]. Clinical Nephrology, 1995,44(3):141- 147.
  • 7[7] Mishiro S, Hoshi Y, Takeda K, et al. Non-A, Non-B hepatitis specifi c antibodies at host derived epitope: implication for an autoimmune process[J] . Lancet, 1990,336(12):1400-1403.
  • 8[8] Nagata S, Golstein P. The Fas death factor[J]. Science, 1995,267:1449.
  • 9[9] Nagata S, Suda T. Fas and Fas ligand: Lpr and gld mutations[J]. Immunol ogy Today, 1995,16(1):39-43.
  • 10[10] Krammer PH, Dhein J, Walczak H, et al. The role of APO-1-me diated apoptosis in the immune system[J]. Immunol Rev, 1994,142:175-190.

共引文献7

同被引文献11

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部